{"eventGroups":[{"description":"Phase I patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 1\n* 10 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* CpG 7909 (Agatolimod Sodium) doses will be assigned in groups of 6 patients. Dose levels will escalate in each group until maximum tolerability is attained (starting at 0.08 mg/kg and sequentially escalating to 0.16 mg/kg, 0.32 mg/kg, 0.48 mg/kg). Doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"EG000","otherNumAffected":30,"otherNumAtRisk":30,"seriousNumAffected":14,"seriousNumAtRisk":30,"title":"Phase I"},{"description":"Phase II patients will receive the following treatment:\n\n* 250 mg/m\\^2 Rituximab IV on days 1, 8, and 15 of a 27 day cycle\n* 5 mCi (Indium-111), 1.6 mg Ibritumomab IV on day 8\n* 0.48 mg/kg CpG 7909 (Agatolimod Sodium) doses will be taken day 6, 13, 20, and 27 of a 27 day cycle.\n* 0.4 mCi/kg Yttrium-90 Zevalin IV on day 15","id":"EG001","otherNumAffected":8,"otherNumAtRisk":8,"seriousNumAffected":5,"seriousNumAtRisk":8,"title":"Phase II"}],"frequencyThreshold":"0","otherEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":30,"numEvents":40},{"groupId":"EG001","numAffected":8,"numAtRisk":8,"numEvents":15}],"term":"Hemoglobin decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Arrhythmia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Abdominal pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Diarrhea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Nausea"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Chills"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":30,"numEvents":5},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Fatigue"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Localized edema"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"General disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Abdominal infection"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":30,"numEvents":3},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Sinusitis"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Alanine aminotransferase increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Blood bilirubin increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":30,"numEvents":63},{"groupId":"EG001","numAffected":4,"numAtRisk":8,"numEvents":7}],"term":"Leukocyte count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":30,"numEvents":37},{"groupId":"EG001","numAffected":4,"numAtRisk":8,"numEvents":5}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":30,"numEvents":34},{"groupId":"EG001","numAffected":5,"numAtRisk":8,"numEvents":7}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Anorexia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Blood glucose increased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Neck pain"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Neurological disorder NOS"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Syncope vasovagal"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Petechiae"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":30,"numEvents":4},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Rash desquamating"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Sweating"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Hypotension"}],"seriousEvents":[{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":30,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Febrile neutropenia"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Constipation"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":30,"numEvents":7},{"groupId":"EG001","numAffected":0,"numAtRisk":8,"numEvents":0}],"term":"Leukocyte count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":30,"numEvents":11},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Neutrophil count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Investigations","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":30,"numEvents":20},{"groupId":"EG001","numAffected":4,"numAtRisk":8,"numEvents":7}],"term":"Platelet count decreased"},{"assessmentType":"SYSTEMATIC_ASSESSMENT","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 6","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":30,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":8,"numEvents":1}],"term":"Tumor pain"}]}